Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma
Open Access
- 1 December 2010
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 3 (6) , 336-IN1
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cellsBMC Cancer, 2009
- Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met–dependent tumors in animal modelsMolecular Cancer Therapeutics, 2009
- c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migrationCarcinogenesis, 2009
- Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and GrowthCancer Research, 2008
- Inhibition of c-Met as a Therapeutic Strategy for Esophageal AdenocarcinomaNeoplasia, 2006
- A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivoClinical Cancer Research, 2006
- Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.Clinical Cancer Research, 2006
- Mechanisms and significance of bifunctional NK4 in cancer treatmentBiochemical and Biophysical Research Communications, 2005
- Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridizationJournal of neurosurgery. Pediatrics, 2004
- Dose dependency of time of onset of radiation-induced growth hormone deficiencyThe Journal of Pediatrics, 1991